Braveheart Bio filed for an initial public offering, setting out a path to scale its lead oral cardiac myosin inhibitor, BHB-1893, for hypertrophic cardiomyopathy. The company plans to advance worldwide Phase III studies, with an obstructive HCM trial expected to start in the second half of 2026 and a nonobstructive HCM study planned for early 2027. Braveheart’s program stems from a licensing deal with Jiangsu Hengrui Pharmaceuticals, originally valued at up to $1 billion, and it recently reported encouraging Phase II results across both major HCM subtypes (NCT06516068). The IPO filing did not disclose a target raise amount, while listing use of proceeds primarily for development progression. Investors will watch how Braveheart positions the clinical evidence and manufacturing readiness required for a worldwide Phase III launch, particularly as the IPO calendar opens with multiple biotech listings underway.